ArticleJCO precision oncology2025
Multicancer Early Detection Blood Test Performance in Cancer Survivors From the PATHFINDER Study.
Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MOCDT: multi-cancer detection and tissue-of-origin classification via cfDNA multi-modal integration.Bioinformatics (Oxford, England) · 2026Article
- Impact of Multicancer Screening on Late-Stage Cancer at Diagnosis in Breast Cancer Survivors: A Modeling Study.JCO precision oncology · 2026Article
- Advances in Breast Cancer Diagnostics: From Screening to Precision Medicine.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCancer survivors are at risk for recurrence and second primaries, yet often lack clear guidance for long-term surveillance.
methodsWe assessed the performance of a blood-based multicancer early detection (MCED) test in 1,609 survivors who participated in PATHFINDER, a prospective study of adults without current suspicion of cancer.
resultsPrevious cancers included breast (47%), melanoma (10%), prostate (9%), colorectal (4%), and lymphoma (4%). Average time since diagnosis was 11.2 years, and a cancer signal was detected in 1.2% (20/1,609). Ten new cancer diagnoses occurred: 5 second primaries (stage I uterine, stage II sarcoma, stage III ovarian, stage IV lymphoma, and stage IV colorectal) 8-15 years after original diagnosis and five recurrences (breast cancer) 4-11 years after original diagnosis. Test performance metrics were similar in those with and without previous cancer history.
conclusionThese findings highlight the potential of MCED tests to address a significant unmet need in long-term surveillance of survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.